Efficacy, safety, and target engagement of dazukibart, an IFNβ specific monoclonal antibody, in adults with dermatomyositis: a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial
Stanford University · Mayo Clinic in Arizona · +14 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
42
total citations
- FWCI
- 44.38
- Percentile
- 100%
- References
- 24
Citations per year
Authors
26Topics & keywords
Topics
Keywords
- Medicine
- Dermatomyositis
- Placebo
- Monoclonal antibody
- Double blind
- Internal medicine
- Physical therapy
- Monoclonal
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.